Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus

Lupus

Volumn 5, Issue 6, 1996, Pages 598-601

  Bengtsson, A ^a   Zoller B ^a   De Frutos, P G ^a   Dahlback B ^a   Sturfelt, G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

aCL; APC resistance; Factor V; SLE; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BRAIN INFARCTION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VALVULAR HEART DISEASE; VEIN THROMBOSIS; ADOLESCENT; BLOOD; CHILD; GENETICS; IMMUNOLOGY; MIDDLE AGED; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; CHILD; FACTOR V; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POINT MUTATION; THROMBOSIS;

EID: 0030300003     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500607     Document Type: Article

References (47)

1. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43.
2. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738.
3. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993, 90: 1004-1008.
4. Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993.
5. Koster T et al. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
6. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521.
7. Faioni EM et al. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071.
8. Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinol 1994; 5: 51-57.
9. Zöller B, Dahlbäck B. Resistance to activated protein C caused by a factor V gene mutation. Current Opinion in Hematology 1995; 2: 358-364.
10. Bertina RM et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
11. Sun X, Evatt BL, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125.
12. Greengard JA et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-1363.
13. Voorberg J et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536.
14. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
15. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
16. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-4057
17. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
18. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
19. Vandenbroucke JP et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
20. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-213.
21. Fauno P et al. Association between activated protein C resistance and postoperative deep vein thrombosis. Thromb Haemost 1995; 73: 1371 (Abstract).
22. Davies KA et al. Factor V Leiden mutation and venous thrombosis. Lancet 1995; 345: 132-133.
23. Matsuda J et al. Resistance to activated protein C in systemic lupus erythematosus patients with antiphospholipid antibodies. Eur J Haematol 1994; 53: 188-189.
24. Hampton KK, Path MRC, Preston FE, Greaves M. Resistance to activated protein C. N Engl J Med 1994; 331: 130.
25. Halbmayer WM, Haushofer A, Schön R, Fischer M. Influence of lupus anticoagulant on a commercial available kit for APC-resistance. Thromb Haemost 1994; 72: 643-651.
26. Gschwandtner ME, Lechner K, Pabinger I. Erroneously low APC ratio in patients with lupus anticoagulant. Ann Hematol 1995; 70: 169-170.
27. Pistiner M et al. Lupus erythematosus in the 1980's: a survey of 570 patients. Semin Arthritis Rheum 1991; 21: 55.
28. Sturfelt G et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine Baltimore 1992; 71: 216-223.
29. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine Baltimore 1989; 68: 141-150.
30. Boumpas DT et al. Systemic Lupus Erythematosus: Emerging Concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123: 42-53.
31. Goodnight SH. Antiphospholipid antibodies and thrombosis. Current Opinion in Hematology 1994; 1: 354-361.
32. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 11: 370-373.
33. Feinstein DI. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985; 313: 1348-1350.
34. Khamashta MA et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
35. Sturfelt G et al. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 382-388.
36. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
37. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16: 1215
38. Dahlbäck B, Nilsson IM, Frohm B. Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 1983; 62: 218-225.
39. Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995; 73: 743-745.
40. Matsuda J et al. Resistance to activated protein C activity of an anti-beta(2)-glycoprotein i antibody in the presence of beat(2)-glycoprotein I. Br J Haematol 1995, 90: 204-206.
41. Beuchamp NJ et al. High prevalence of mutation in the factor V gene within the U.K. population; relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-222.
42. 2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
43. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462.
44. Marciniak E, Romond EH. Impaired catalytic function of activated protein C and its cofactor protein S by antiphospholipid antibodies. Blood 1989; 74: 2426-2432.
45. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107.
46. Nihoyannopoulos P et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990; 82: 369-375.
47. Reilly PA et al. Mitral stenosis in systemic lupus erythematosus. Successful management by mitral valve replacement. Eur J Cardiothorac Surg 1988; 2: 377-379.